{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T09:01:00Z","timestamp":1783760460561,"version":"3.55.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.jpba.2011.11.033","type":"journal-article","created":{"date-parts":[[2011,12,11]],"date-time":"2011-12-11T08:35:37Z","timestamp":1323592537000},"page":"184-190","source":"Crossref","is-referenced-by-count":35,"special_numbering":"C","title":["Chromatography approaches for early screening of the phospholipidosis-inducing potential of pharmaceuticals"],"prefix":"10.1016","volume":"61","author":[{"given":"Zhengjin","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Reilly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jpba.2011.11.033_bib0005","doi-asserted-by":"crossref","first-page":"5533","DOI":"10.1016\/j.febslet.2006.08.061","article-title":"Drug-induced phospholipidosis","volume":"580","author":"Anderson","year":"2006","journal-title":"FEBS Lett."},{"key":"10.1016\/j.jpba.2011.11.033_bib0010","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1177\/153537020122600903","article-title":"Drug-induced phospholipidosis: are there functional consequences?","volume":"226","author":"Reasor","year":"2001","journal-title":"Exp. Biol. Med."},{"key":"10.1016\/j.jpba.2011.11.033_bib0015","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S0031-6997(25)00049-3","article-title":"Cationic amphiphilic drugs and phospholipid storage disorder","volume":"42","author":"Kodavanti","year":"1990","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jpba.2011.11.033_bib0020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1177\/019262339702500111","article-title":"Cationic amphiphilic drug-induced phospholipidosis","volume":"25","author":"Halliwell","year":"1997","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0025","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0041-008X(89)90054-9","article-title":"A review of the biology and toxicologic implications of the induction of lysosomal lamellar bodies by drugs","volume":"97","author":"Reasor","year":"1989","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0030","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/0041-008X(89)90061-6","article-title":"Amiodarone-induced pulmonary toxicity in rats: biochemical and pharmacological characteristics","volume":"97","author":"Reasor","year":"1989","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0035","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/01926230701196414","article-title":"Phospholipidosis in nonclinical toxicity studies","volume":"35","author":"Berridge","year":"2007","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0040","unstructured":"Cerep, Phospholipidosis, ADME-Tox Application note 2009."},{"key":"10.1016\/j.jpba.2011.11.033_bib0045","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1002\/cmdc.200900052","article-title":"Screening for the drug\u2013phospholipidosis interaction: correlation to phospholipidosis","volume":"4","author":"Alakoskela","year":"2009","journal-title":"ChemMedChem"},{"key":"10.1016\/j.jpba.2011.11.033_bib0050","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/jac\/42.6.761","article-title":"Lysosomal alterations induced in cultured rat fibroblasts by long-term exposure to low concentrations of azithromycin","volume":"42","author":"Van Bambeke","year":"1998","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.jpba.2011.11.033_bib0055","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/0006-2952(91)90208-M","article-title":"Effect of amiodarone on the phospholipid and lamellar body content of lymphoblasts in vitro and peripheral blood lymphocytes in vivo","volume":"41","author":"Hostetler","year":"1991","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0060","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1016\/S0006-2952(01)00823-1","article-title":"Analysis of two matrix metalloproteinase inhibitors and their metabolites for induction of phospholipidosis in rat and human hepatocytes","volume":"62","author":"Gum","year":"2001","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0065","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3109\/15376519109044560","article-title":"An in vitro fluorescence assay for the detection of drug-induced cytoplasmic lamellar bodies","volume":"1","author":"Ulrich","year":"1991","journal-title":"Toxicol. Methods"},{"key":"10.1016\/j.jpba.2011.11.033_bib0070","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1093\/toxsci\/kfj067","article-title":"Establishment of an in vitro high-throughput screening assay for detecting phospholipidosis-inducing potential","volume":"90","author":"Kasahara","year":"2006","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jpba.2011.11.033_bib0075","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s10565-006-0176-z","article-title":"Validation of an in vitro screen for phospholipidosis using a high content biology platform","volume":"22","author":"Morelli","year":"2006","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0080","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1093\/toxsci\/kfh264","article-title":"A toxicogenomic approach to drug-induced phospholipidosis: analysis of its induction mechanism and establishment of a novel in vitro screening system","volume":"83","author":"Sawada","year":"2005","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jpba.2011.11.033_bib0085","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1021\/jm7013953","article-title":"Assessment of drug\u2013lipid complex formation by a high-throughput langmuir-balance and correlation to phospholipidosis","volume":"51","author":"Vitovic","year":"2008","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2011.11.033_bib0090","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1517\/14740338.5.4.567","article-title":"Drug-induced phospholipidosis: issues and future directions","volume":"5","author":"Reasor","year":"2006","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.jpba.2011.11.033_bib0095","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1165\/ajrcmb\/4.4.369","article-title":"Amiodarone- and desethylamiodarone-induced pulmonary phospholipidosis, inhibition of phospholipases in vivo, and alteration of [14C] amiodarone uptake by perfused lung","volume":"4","author":"Kodavanti","year":"1991","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0100","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0940-2993(04)70180-3","article-title":"Exp Use of physicochemical calculation of pKa and ClogP to predict phospholipidosis-inducing potential","volume":"55","author":"Ploemen","year":"2004","journal-title":"Toxicol. Pathol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0105","doi-asserted-by":"crossref","first-page":"315","DOI":"10.2131\/jts.31.315","article-title":"Physicochemical and cell-based approach for early screening of phospholipidosis-induced potential","volume":"31","author":"Tomizawa","year":"2006","journal-title":"J. Toxicol. Sci."},{"key":"10.1016\/j.jpba.2011.11.033_bib0110","doi-asserted-by":"crossref","first-page":"6980","DOI":"10.1021\/ac200683k","article-title":"Predicting phospholipidosis: a fluorescence noncell based in vitro assay for the determination of drug\u2013phospholipid complex formation in early drug discovery","volume":"83","author":"Zhou","year":"2011","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2011.11.033_bib0115","series-title":"Abstracts of Papers of the American Chemical Society, vol. 228","article-title":"Prediction of intestinal and blood brain barrier permeability utilizing immobilized artifical membrane chromatography","author":"Adejare","year":"2004"},{"key":"10.1016\/j.jpba.2011.11.033_bib0120","doi-asserted-by":"crossref","first-page":"3550","DOI":"10.1021\/ac00115a026","article-title":"Predicting drug\u2013membrane interactions by HPLC: structural requirements of chromatographic surfaces","volume":"67","author":"Liu","year":"1995","journal-title":"Anal. Chem."},{"key":"10.1016\/j.jpba.2011.11.033_bib0125","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1021\/jm00004a004","article-title":"IAM chromatography: an in vitro screen for predicting drug membrane permeability","volume":"38","author":"Pidgeon","year":"1995","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2011.11.033_bib0130","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1023\/A:1011904311149","article-title":"Potential of immobilized artificial membranes for predicting drug penetration across the blood\u2013brain barrier","volume":"15","author":"Reichel","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2011.11.033_bib0135","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1023\/A:1016156927420","article-title":"Molecular factors influencing retention on immobilized artificial membranes (IAM) compared to partitioning in liposomes and n-octanol","volume":"19","author":"Taillardat-Bertschinger","year":"2002","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2011.11.033_bib0140","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1007\/s11095-004-7685-3","article-title":"Interaction of basic drugs with lipid bilayers using liposome electrokinetic chromatography","volume":"21","author":"Carrozzino","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.jpba.2011.11.033_bib0145","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.chroma.2005.04.008","article-title":"pH Effects on drug interactions with lipid bilayers by liposome electrokinetic chromatography","volume":"1079","author":"Carrozzino","year":"2005","journal-title":"J. Chromatogr. A"},{"key":"10.1016\/j.jpba.2011.11.033_bib0150","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1002\/elps.200800236","article-title":"A method for rapidly predicting drug tissue distribution using surfactant vesicle electrokinetic chromatography","volume":"29","author":"Jiang","year":"2008","journal-title":"Electrophoresis"},{"key":"10.1016\/j.jpba.2011.11.033_bib0155","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1002\/elps.200500647","article-title":"Investigation of vesicle electrokinetic chromatography as an in vitro assay for the estimation of intestinal permeability of pharmaceutical drug candidates","volume":"27","author":"Pascoe","year":"2006","journal-title":"Electrophoresis"},{"key":"10.1016\/j.jpba.2011.11.033_bib0160","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1023\/A:1024778329320","article-title":"A cell-based approach for the early assessment of the phospholipidogenic potential in pharmaceutical research and drug development","volume":"19","author":"Casartelli","year":"2003","journal-title":"Cell Biol. Toxicol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0165","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/1520-6017(200008)89:8<1085::AID-JPS13>3.0.CO;2-N","article-title":"Rapid-gradient HPLC method for measuring drug interactions with immobilized artificial membrane: comparison with other lipophilicity measures","volume":"89","author":"Valko","year":"2000","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2011.11.033_bib0170","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1002\/jps.10494","article-title":"Fast gradient HPLC method to determine compounds binding to human serum albumin. Relationships with octanol\/water and immobilized artificial membrane lipophilicity","volume":"92","author":"Valko","year":"2003","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.jpba.2011.11.033_bib0175","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/S1570-0232(03)00250-2","article-title":"Pharmaceutical profiling method for lipophilicity and integrity using LC\/MS","volume":"791","author":"Kerns","year":"2003","journal-title":"J. Chromatogr. B"},{"key":"10.1016\/j.jpba.2011.11.033_bib0180","doi-asserted-by":"crossref","first-page":"6958","DOI":"10.1021\/jm050957i","article-title":"Estimation of volume of distribution in humans from high throughput HPLC-based measurements of human serum albumin binding and immobilized artificial membrane partitioning","volume":"49","author":"Hollosy","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.jpba.2011.11.033_bib0185","doi-asserted-by":"crossref","first-page":"346","DOI":"10.3181\/00379727-211-43979","article-title":"Effects of amiodarone-induced phospholipidosis on pulmonary host defense functions in rats","volume":"211","author":"Reasor","year":"1996","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.jpba.2011.11.033_bib0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3181\/00379727-196-43158A","article-title":"Amiodarone pulmonary toxicity: morphologic and biochemical features","volume":"196","author":"Reasor","year":"1991","journal-title":"Proc. Soc. Exp. Biol. Med."},{"key":"10.1016\/j.jpba.2011.11.033_bib0195","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/BF00341016","article-title":"Lipidosis-like alterations in cultured macrophages exposed to local anaesthetics","volume":"55","author":"J\u00e4gel","year":"1984","journal-title":"Arch. Toxicol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0200","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF00501152","article-title":"Fenfluramine-induced ultrastructural alterations in tissues of rats and guinea pigs","volume":"285","author":"L\u00fcllmann-Rauch","year":"1974","journal-title":"Naunyn Schmiedeberg's Arch. Pharmacol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0205","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/S0301-0082(99)00036-2","article-title":"Antidepressant-induced lipidosis with special reference to tricyclic compounds","volume":"60","author":"Xia","year":"2000","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0210","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/toxsci\/kfm157","article-title":"In vitro detection of drug-induced phospholipidosis using gene expression and fluorescent phospholipid-based methodologies","volume":"99","author":"Nioi","year":"2007","journal-title":"Toxicol. Sci."},{"key":"10.1016\/j.jpba.2011.11.033_bib0215","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/0006-2952(85)90183-2","article-title":"Inhibition of purified lysosomal phospholipase A1 by various beta andrenergic blockers","volume":"34","author":"Pappu","year":"1985","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.jpba.2011.11.033_bib0220","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1517\/17425255.2.5.687","article-title":"In vitro assays and biomarkers for drug-induced phospholipidosis","volume":"2","author":"Monteith","year":"2006","journal-title":"Expert Opin. Drug Metab. Toxicol."}],"container-title":["Journal of Pharmaceutical and Biomedical Analysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708511006844?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0731708511006844?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,15]],"date-time":"2025-03-15T12:43:32Z","timestamp":1742042612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0731708511006844"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":44,"alternative-id":["S0731708511006844"],"URL":"https:\/\/doi.org\/10.1016\/j.jpba.2011.11.033","relation":{},"ISSN":["0731-7085"],"issn-type":[{"value":"0731-7085","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]}}}